DK2231667T3 - Beta-lactamase-hæmmere - Google Patents

Beta-lactamase-hæmmere

Info

Publication number: DK2231667T3
Authority: DK; Denmark
Prior art keywords: beta; lactamase inhibitors; lactamase; inhibitors
Prior art date: 2008-01-18

Application number

DK09701487.2T

Other languages

English (en)

Inventor

Timothy A Blizzard

Helen Chen

Candido Gude

Jeffrey D Hermes

Jason E Imbriglio

Seongkon Kim

Jane Y Wu

Sookhee Ha

Christopher J Mortko

Ian Mangion

Nelo Rivera

Rebecca T Ruck

Michael Shevlin

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-18

Filing date

2009-01-15

Publication date

2013-12-16

2009-01-15 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2013-12-16 Application granted granted Critical

2013-12-16 Publication of DK2231667T3 publication Critical patent/DK2231667T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrrole Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

DK09701487.2T 2008-01-18 2009-01-15 Beta-lactamase-hæmmere DK2231667T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1153308P	2008-01-18	2008-01-18
PCT/US2009/031047 WO2009091856A2 (en)	2008-01-18	2009-01-15	Beta-lactamase inhibitors

Publications (1)

Publication Number	Publication Date
DK2231667T3 true DK2231667T3 (da)	2013-12-16

Family

ID=40642204

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13180969.1T DK2666774T3 (da)	2008-01-18	2009-01-15	Beta-lactamase-hæmmere
DK09701487.2T DK2231667T3 (da)	2008-01-18	2009-01-15	Beta-lactamase-hæmmere

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK13180969.1T DK2666774T3 (da)	2008-01-18	2009-01-15	Beta-lactamase-hæmmere

Country Status (38)

Country	Link
US (2)	US8487093B2 (da)
EP (2)	EP2666774B1 (da)
JP (3)	JP5038509B2 (da)
KR (2)	KR101800610B1 (da)
CN (2)	CN101918407B (da)
AU (1)	AU2009206119C1 (da)
BR (1)	BRPI0906871B1 (da)
CA (1)	CA2712783C (da)
CO (1)	CO6331438A2 (da)
CR (1)	CR11626A (da)
CY (5)	CY1114900T1 (da)
DK (2)	DK2666774T3 (da)
DO (1)	DOP2010000218A (da)
EC (2)	ECSP10010345A (da)
ES (2)	ES2533826T3 (da)
FR (3)	FR20C1030I2 (da)
HN (1)	HN2010001395A (da)
HR (2)	HRP20131123T1 (da)
HU (2)	HUS000504I2 (da)
IL (1)	IL206395A (da)
LT (3)	LTPA2020517I1 (da)
LU (1)	LUC00165I2 (da)
MA (1)	MA32025B1 (da)
ME (1)	ME02089B (da)
MX (1)	MX2010007823A (da)
MY (1)	MY162532A (da)
NI (1)	NI201000115A (da)
NL (2)	NL301051I2 (da)
NO (3)	NO2020023I1 (da)
NZ (1)	NZ586861A (da)
PL (2)	PL2231667T3 (da)
PT (2)	PT2231667E (da)
RS (2)	RS53052B (da)
RU (1)	RU2445314C9 (da)
SI (2)	SI2231667T1 (da)
UA (1)	UA101966C2 (da)
WO (1)	WO2009091856A2 (da)
ZA (1)	ZA201005333B (da)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2231667T3 (pl) *	2008-01-18	2014-01-31	Merck Sharp & Dohme	Inhibitory beta-laktamazy
EP2603514B1 (en)	2010-08-10	2018-07-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103328476B (zh) *	2010-12-22	2016-12-28	明治制果药业株式会社	光学活性二氮杂环辛烷衍生物及其制备方法
US8772490B2 (en)	2010-12-22	2014-07-08	Meiji Seika Pharma Co., Ltd.	Optically active diazabicyclooctane derivatives and process for preparing the same
ES2560404T3 (es) *	2011-06-17	2016-02-18	Astrazeneca Ab	Procesos para preparar compuestos heterocíclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma
EP2748165B1 (en) *	2011-08-27	2016-11-02	Wockhardt Limited	1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
US9006230B2 (en) *	2011-08-30	2015-04-14	Wockhardt Ltd.	1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US9012491B2 (en)	2011-08-31	2015-04-21	Rempex Pharmaceuticals, Inc.	Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8796257B2 (en)	2011-12-02	2014-08-05	Naeja Pharmaceutical Inc.	Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en)	2011-12-02	2016-11-29	Fedora Pharmaceuticals Inc.	Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
CN104159587A (zh) *	2012-01-06	2014-11-19	南佛罗里达大学	组合物、使用方法、以及治疗方法
TW201343646A (zh) *	2012-03-30	2013-11-01	Cubist Pharm Inc	異□唑β－內醯胺酶抑制劑
US8969570B2 (en)	2012-03-30	2015-03-03	Cubist Pharmaceuticals, Inc.	Beta-lactamase inhibitors
US8933232B2 (en)	2012-03-30	2015-01-13	Cubist Pharmaceuticals, Inc.	1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8916709B2 (en)	2012-03-30	2014-12-23	Cubist Pharmaceuticals, Inc.	1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) *	2012-04-02	2014-11-19	Astrazeneca Ab	COMPUESTOS INHIBIDORES DE b LACTAMASA
DK2847327T3 (da)	2012-05-08	2019-03-11	Codexis Inc	Biokatalysatorer og fremgangsmåder til hydroxylering af kemiske forbindelser
US9156858B2 (en)	2012-05-23	2015-10-13	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
CN104334559B (zh) *	2012-05-30	2017-03-22	明治制果药业株式会社	β‑内酰胺酶抑制剂及其制备方法
US10561675B2 (en)	2012-06-06	2020-02-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2013308127B2 (en) *	2012-08-25	2015-08-13	Wockhardt Limited	1,6- Diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
JPWO2014069351A1 (ja) *	2012-11-01	2016-09-08	株式会社カネカ	光学活性二環式ウレア化合物の製造方法
JP6403219B2 (ja) *	2012-12-07	2018-10-10	ベナトルクスファーマシューティカルズ，インク．	ベータ−ラクタマーゼ阻害剤
UA111925C2 (uk)	2012-12-11	2016-06-24	Федора Фармасьютікалз Інк.	БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
JP2016509594A (ja)	2013-01-04	2016-03-31	レンペックス・ファーマシューティカルズ・インコーポレイテッド	ボロン酸誘導体及びその治療的使用
US9101638B2 (en)	2013-01-04	2015-08-11	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
AU2014204046B2 (en)	2013-01-04	2017-02-23	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en)	2013-01-04	2016-01-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en)	2013-01-10	2019-03-13	Venatorx Pharmaceuticals Inc	Beta-lactamase inhibitors
WO2015033191A1 (en) *	2013-03-08	2015-03-12	Wockhardt Limited	A process for preparation of (2s, 5r)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
WO2014135931A1 (en) *	2013-03-08	2014-09-12	Wockhardt Limited	A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
RU2632192C2 (ru) *	2013-03-08	2017-10-03	Вокхардт Лимитед	Способ получения натриевой соли (2s,5r)-2-карбоксамидо-7-оксо-6-сульфоокси-1,6-диазабицикло[3.2.1]октана
MX2015011721A (es) *	2013-03-08	2015-12-01	Wockhardt Ltd	Proceso para la preparacion de (2s,5r) -7-oxo-6-sulfooxi-2-[((3r)- pirrolidin-3-carbonil) carbonil hidrazino]-1,6-diaza-biciclo[3.2.1 ] octano.
KR101774132B1 (ko)	2013-03-08	2017-09-01	욱크하르트 리미티드	(2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
AU2013380574B2 (en) *	2013-03-08	2016-07-07	Wockhardt Limited	A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
US9944658B2 (en)	2013-03-14	2018-04-17	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
WO2014152996A1 (en) *	2013-03-14	2014-09-25	Cubist Pharmaceuticals, Inc.	Crystalline form of a beta-lactamase inhibitor
BR112015030470B1 (pt) *	2013-06-10	2022-08-16	Merck Sharp & Dohme Corp	Processo para preparar 4-((1,r,2s,5r)-6-(benzilóxi)-7-oxo1,6-diazabiciclo[3.2.1]octano-2- carboxamido)piperidina-1-carboxilato de terc-butila, e composto
MY176278A (en)	2013-09-24	2020-07-27	Meiji Seika Pharma Co Ltd	Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) *	2013-10-02	2015-04-09	Cubist Pharmaceuticals, Inc.	B-lactamase inhibitor picoline salt
EP3067355B1 (en)	2013-10-08	2020-12-16	Meiji Seika Pharma Co., Ltd.	Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
EP3074397B1 (en)	2013-11-26	2019-02-13	Wockhardt Limited	A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
HRP20190501T1 (hr)	2014-03-24	2019-05-03	Novartis Ag	Monobaktam organski spojevi za liječenje bakterijskih infekcija
WO2015150891A1 (en) *	2014-03-29	2015-10-08	Wockhardt Limited	A process for preparation of trans-sulfuric acid mono-[2-(5-azetidin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo [3.2.1]oct-6-yl]ester
IN2014MU01196A (da) *	2014-03-29	2015-10-02	Wockhardt Ltd
RS59488B1 (sr)	2014-05-05	2019-12-31	Rempex Pharmaceuticals Inc	Sinteza boronatnih soli i njihove upotrebe
US9687497B1 (en)	2014-05-05	2017-06-27	Rempex Pharmaceuticals, Inc.	Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2016015093A (es)	2014-05-19	2017-03-27	Rempex Pharmaceuticals Inc	Derivados de acido boronico y sus usos terapeuticos.
US9511142B2 (en)	2014-06-11	2016-12-06	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
KR20220065084A (ko)	2014-06-11	2022-05-19	베나토알엑스 파마슈티컬스, 인크.	베타-락타마제 억제제
EA201692301A1 (ru)	2014-07-01	2017-06-30	Ремпекс Фармасьютикалз, Инк.	Производные бороновой кислоты и их терапевтическое применение
ME03357B (me) *	2014-11-17	2019-10-20	Entasis Therapeutics Ltd	Kombinovana terapija za lečenje rezistentnih bakterijsкih infekcija
US10662205B2 (en)	2014-11-18	2020-05-26	Qpex Biopharma, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3227306B1 (en)	2014-12-02	2020-07-15	Merck Sharp & Dohme Corp.	Process for the preparation of tert-butyl 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
RU2732129C2 (ru)	2014-12-05	2020-09-11	Мейдзи Сейка Фарма Ко., Лтд.	Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
US20180051041A1 (en)	2015-03-17	2018-02-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
JP2018510190A (ja) *	2015-03-31	2018-04-12	ミュタビリスＭｕｔａｂｉｌｉｓ	複素環式化合物及びそれらの細菌感染症の予防または治療のための使用
CA2983674A1 (en) *	2015-05-07	2016-11-10	Mutabilis	Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017044828A1 (en)	2015-09-11	2017-03-16	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
EP3281942A4 (en) *	2015-09-16	2018-08-15	Xuanzhu Pharma Co., Ltd.	B-lactamase inhibitor and application thereof
BR112018006422A2 (pt)	2015-10-02	2018-10-09	Legochem Biosciences Inc	composições e métodos para inibir beta-lactamase
WO2017100537A1 (en)	2015-12-10	2017-06-15	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
WO2017098425A1 (en) *	2015-12-11	2017-06-15	Wockhardt Limited	7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
EP3411359B1 (en)	2016-02-04	2021-10-13	Merck Sharp & Dohme Corp.	Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN108778270B (zh) *	2016-03-31	2021-07-30	吉林四环制药有限公司	一种抗菌组合物及其用途
WO2017213758A1 (en)	2016-06-09	2017-12-14	Codexis, Inc.	Biocatalysts and methods for hydroxylation of chemical compounds
EP3478693B1 (en)	2016-06-30	2021-07-21	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP3494121B1 (en)	2016-08-04	2021-10-06	Venatorx Pharmaceuticals, Inc.	Boron-containing compounds
KR102537340B1 (ko) *	2016-09-16	2023-05-26	엔타시스 테라퓨틱스 리미티드	베타-락타마제 억제제 화합물
WO2018053057A2 (en) *	2016-09-19	2018-03-22	Merck Sharp & Dohme Corp.	Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar) *	2016-09-28	2019-03-26	Novartis Ag	مثبطات بيتا-لاكتاماز
CN108078982B (zh) *	2016-11-21	2020-02-07	天津大学	脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
SG11201908181XA (en)	2017-03-06	2019-10-30	Venatorx Pharmaceuticals Inc	Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN108619141B (zh) *	2017-03-16	2021-09-10	山东轩竹医药科技有限公司	一种抗菌组合物及其用途
SG11201909443YA (en)	2017-05-08	2019-11-28	Entasis Therapeutics Inc	Compounds and methods for treating bacterial infections
US10085999B1 (en)	2017-05-10	2018-10-02	Arixa Pharmaceuticals, Inc.	Beta-lactamase inhibitors and uses thereof
WO2018218190A1 (en)	2017-05-26	2018-11-29	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
WO2018218154A1 (en)	2017-05-26	2018-11-29	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
ES2946917T3 (es)	2017-07-21	2023-07-27	Antabio Sas	Compuestos químicos
CN109568323B (zh) *	2017-09-29	2022-09-30	吉林四环制药有限公司	抗菌组合物及其用途
JP7377545B2 (ja)	2017-10-11	2023-11-10	キューペックスバイオファーマ，インコーポレイテッド	ボロン酸誘導体およびその合成
EP3719020B1 (en)	2017-12-01	2022-09-21	Qilu Pharmaceutical Co., Ltd.	Crystal form of beta-lactamase inhibitor and preparation method therefor
CN109956941B (zh) *	2017-12-25	2020-08-04	新发药业有限公司	一种阿维巴坦的简便制备方法
EP3744722A4 (en) *	2018-01-25	2021-11-03	Suzhou Sinovent Pharmaceuticals Co., Ltd.	Ss-LACTAMASE INHIBITOR AND ITS USE
CA3097127A1 (en)	2018-04-20	2019-10-24	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP3572411A1 (en)	2018-05-21	2019-11-27	Antabio SAS	Thiazole derivatives as metallo-beta-lactamase inhibitors
US12173018B2 (en)	2018-05-25	2024-12-24	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
FI3833665T3 (fi) *	2018-08-09	2023-10-09	Antabio Sas	Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
EP3670512A1 (en) *	2018-12-18	2020-06-24	Antabio SAS	Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en)	2018-08-09	2024-02-20	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11897844B2 (en) *	2018-09-21	2024-02-13	Api Corporation	Method for producing amino acid derivatives
CA3114618C (en) *	2018-10-01	2023-09-05	Arixa Pharmaceuticals, Inc.	Derivatives of relebactam and uses thereof
CN111072660B (zh) *	2018-10-22	2021-05-18	新发药业有限公司	一种瑞来巴坦的简便制备方法
SG11202108905UA (en)	2019-03-12	2021-09-29	Arixa Pharmaceuticals Inc	Crystalline form of an avibactam derivative
US12162883B2 (en)	2019-04-26	2024-12-10	Merck Sharp & Dohme Llc	Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
JP7647110B2 (ja) *	2020-01-22	2025-03-18	日油株式会社	ポリエーテルエステル化合物
WO2022047603A1 (en)	2020-09-01	2022-03-10	Ningxia Academy Of Agriculture And Forestry Sciences	Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) *	2020-09-07	2022-03-10	Ningxia Academy Of Agriculture And Forestry Sciences	Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) *	2020-09-10	2022-03-29	山东安信制药有限公司	一种瑞来巴坦的制备方法
CN115605480B (zh)	2021-05-07	2024-04-05	宁夏农林科学院	磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
US11814385B2 (en) *	2021-06-25	2023-11-14	University Of South Florida	Small molecule inhibitors targeting Clostridioides difficile sporulation
US20250302846A1 (en) *	2022-05-11	2025-10-02	The Regents Of The University Of Colorado A Body Corporate	Antibiotic composition and methods of use thereof
CN117384169B (zh) *	2022-07-05	2025-10-17	福安药业集团重庆三禾兴医药科技有限公司	一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途
GB202306826D0 (en)	2023-05-09	2023-06-21	Adjutec Pharma As	Therapy
GB202306833D0 (en)	2023-05-09	2023-06-21	Adjutec Pharma As	Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4616038A (en)	1978-07-24	1986-10-07	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4880793A (en)	1978-07-24	1989-11-14	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US5071843A (en)	1978-07-24	1991-12-10	Merck & Co., Inc.	Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4539208A (en)	1980-09-17	1985-09-03	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
ATE140702T1 (de)	1991-04-11	1996-08-15	Hoffmann La Roche	Beta-lactame
DE69416869T2 (de)	1993-12-29	1999-07-01	Pfizer Inc., New York, N.Y.	Diazabicyclische neurokinin antagonisten
JP3199300B2 (ja)	1994-05-09	2001-08-13	三共株式会社	１−メチルカルバペネム誘導体
EP0882728B1 (en)	1995-12-21	2002-09-04	Sankyo Company Limited	1-methylcarbapenem derivatives
JP2965922B2 (ja) *	1995-12-21	1999-10-18	三共株式会社	１−メチルカルバペネム誘導体
JP2955276B2 (ja)	1997-06-19	1999-10-04	三共株式会社	１−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja)	1998-03-19	2010-06-30	富山化学工業株式会社	５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
US6472406B1 (en)	1999-07-06	2002-10-29	Methylgene, Inc.	Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
TR200200360T2 (tr) *	1999-08-10	2002-06-21	British Biotech Pharmaceuticals Limited	Antibakteriyel aktif maddeler.
FR2812635B1 (fr) *	2000-08-01	2002-10-11	Aventis Pharma Sa	Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) *	2000-11-16	2002-07-31	Sankyo Co Ltd	１−メチルカルバペネム誘導体
RU2247725C2 (ru)	2000-11-16	2005-03-10	Санкио Компани, Лимитед	Производные 1-метилкарбапенема
FR2825705B1 (fr)	2001-06-08	2005-05-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) *	2002-01-28	2006-10-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja)	2002-05-15	2004-02-12	Sankyo Co Ltd	１−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) *	2002-12-06	2008-10-21	Novexel	Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
EP1648859B1 (en)	2003-07-09	2013-02-27	Paratek Pharmaceuticals, Inc.	Substituted tetracycline compounds
US6984652B2 (en)	2003-09-05	2006-01-10	Warner-Lambert Company Llc	Gyrase inhibitors
WO2005033129A1 (de) *	2003-10-01	2005-04-14	Bayer Healthcare Ag	Antibakterielle amid-makrozyklen
WO2005082050A2 (en)	2004-02-24	2005-09-09	Ssci, Inc.	Analysis and screening of solid forms using the atomic pair distribution function
CA2629570C (en) *	2005-12-07	2012-11-27	Basilea Pharmaceutica Ag	Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CA2664296A1 (en)	2006-09-27	2008-04-03	Merck & Co., Inc.	Novel inhibitors of beta-lactamase
PL2231667T3 (pl) *	2008-01-18	2014-01-31	Merck Sharp & Dohme	Inhibitory beta-laktamazy

2009
- 2009-01-15 PL PL09701487T patent/PL2231667T3/pl unknown
- 2009-01-15 ES ES13180969.1T patent/ES2533826T3/es active Active
- 2009-01-15 MX MX2010007823A patent/MX2010007823A/es active IP Right Grant
- 2009-01-15 PL PL13180969T patent/PL2666774T3/pl unknown
- 2009-01-15 CN CN200980102425.0A patent/CN101918407B/zh active Active
- 2009-01-15 ME MEP-2013-511A patent/ME02089B/me unknown
- 2009-01-15 KR KR1020167021668A patent/KR101800610B1/ko active Active
- 2009-01-15 HR HRP20131123AT patent/HRP20131123T1/hr unknown
- 2009-01-15 SI SI200930777T patent/SI2231667T1/sl unknown
- 2009-01-15 MY MYPI2010003255A patent/MY162532A/en unknown
- 2009-01-15 CN CN201210277503.4A patent/CN102827067B/zh active Active
- 2009-01-15 EP EP13180969.1A patent/EP2666774B1/en active Active
- 2009-01-15 RS RS20130511A patent/RS53052B/sr unknown
- 2009-01-15 PT PT97014872T patent/PT2231667E/pt unknown
- 2009-01-15 WO PCT/US2009/031047 patent/WO2009091856A2/en not_active Ceased
- 2009-01-15 KR KR1020107015963A patent/KR101648728B1/ko active Active
- 2009-01-15 ES ES09701487T patent/ES2433744T3/es active Active
- 2009-01-15 PT PT131809691T patent/PT2666774E/pt unknown
- 2009-01-15 DK DK13180969.1T patent/DK2666774T3/da active
- 2009-01-15 DK DK09701487.2T patent/DK2231667T3/da active
- 2009-01-15 AU AU2009206119A patent/AU2009206119C1/en active Active
- 2009-01-15 US US12/812,763 patent/US8487093B2/en active Active
- 2009-01-15 CA CA2712783A patent/CA2712783C/en active Active
- 2009-01-15 JP JP2010543219A patent/JP5038509B2/ja active Active
- 2009-01-15 RU RU2010134425/04A patent/RU2445314C9/ru active
- 2009-01-15 UA UAA201010164A patent/UA101966C2/ru unknown
- 2009-01-15 EP EP09701487.2A patent/EP2231667B1/en active Active
- 2009-01-15 SI SI200931147T patent/SI2666774T1/sl unknown
- 2009-01-15 BR BRPI0906871-6A patent/BRPI0906871B1/pt active IP Right Grant
- 2009-01-15 NZ NZ586861A patent/NZ586861A/en unknown
- 2009-01-15 RS RS20150154A patent/RS53862B1/sr unknown
2010
- 2010-06-15 IL IL206395A patent/IL206395A/en active IP Right Grant
- 2010-06-30 NI NI201000115A patent/NI201000115A/es unknown
- 2010-07-12 HN HN2010001395A patent/HN2010001395A/es unknown
- 2010-07-15 EC EC2010010345A patent/ECSP10010345A/es unknown
- 2010-07-16 MA MA33026A patent/MA32025B1/fr unknown
- 2010-07-16 DO DO2010000218A patent/DOP2010000218A/es unknown
- 2010-07-21 CO CO10088709A patent/CO6331438A2/es active IP Right Grant
- 2010-07-27 ZA ZA2010/05333A patent/ZA201005333B/en unknown
- 2010-08-10 CR CR11626A patent/CR11626A/es unknown
- 2010-10-26 EC EC2010010568A patent/ECSP10010568A/es unknown
2011
- 2011-05-26 JP JP2011118249A patent/JP5597164B2/ja active Active
2012
- 2012-05-22 JP JP2012116243A patent/JP5422020B2/ja active Active
2013
- 2013-06-06 US US13/911,549 patent/US20130274475A1/en not_active Abandoned
- 2013-12-03 CY CY20131101079T patent/CY1114900T1/el unknown
2015
- 2015-03-10 HR HRP20150269TT patent/HRP20150269T1/hr unknown
- 2015-03-23 CY CY20151100288T patent/CY1116243T1/el unknown
2020
- 2020-06-25 NL NL301051C patent/NL301051I2/nl unknown
- 2020-06-25 NL NL301050C patent/NL301050I2/nl unknown
- 2020-06-30 LU LU00165C patent/LUC00165I2/fr unknown
- 2020-07-03 LT LTPA2020517C patent/LTPA2020517I1/lt unknown
- 2020-07-03 LT LTPA2020518C patent/LTC2666774I2/lt unknown
- 2020-07-03 LT LTPA2020516C patent/LTC2231667I2/lt unknown
- 2020-07-09 HU HUS2000024C patent/HUS000504I2/hu unknown
- 2020-07-09 HU HUS2000023C patent/HUS2000023I1/hu unknown
- 2020-07-10 FR FR20C1030C patent/FR20C1030I2/fr active Active
- 2020-07-10 FR FR20C1031C patent/FR20C1031I2/fr active Active
- 2020-07-10 FR FR20C1032C patent/FR20C1032I2/fr active Active
- 2020-07-15 CY CY2020023C patent/CY2020023I2/el unknown
- 2020-07-15 CY CY2020025C patent/CY2020025I2/el unknown
- 2020-07-15 CY CY2020024C patent/CY2020024I2/el unknown
- 2020-08-10 NO NO2020023C patent/NO2020023I1/no unknown
- 2020-08-10 NO NO2020024C patent/NO2020024I1/no unknown
- 2020-08-10 NO NO2020022C patent/NO2020022I1/no unknown

Also Published As

Publication number	Publication date
CA2712783C (en)	2013-03-19
FR20C1032I2 (fr)	2022-07-29
EP2666774B1 (en)	2015-01-07
HUS2000024I1 (hu)	2021-03-29
KR101800610B1 (ko)	2017-11-23
CA2712783A1 (en)	2009-07-23
SI2666774T1 (sl)	2015-04-30
UA101966C2 (en)	2013-05-27
RS53862B1 (sr)	2015-08-31
KR101648728B1 (ko)	2016-08-17
CY2020023I1 (el)	2020-11-25
HK1143809A1 (en)	2011-01-14
EP2666774A1 (en)	2013-11-27
CY1114900T1 (el)	2016-12-14
AU2009206119B2 (en)	2012-06-07
BRPI0906871B1 (pt)	2021-09-28
NL301051I2 (nl)	2020-09-03
NO2020022I1 (no)	2020-08-10
LTC2231667I2 (lt)	2021-07-26
US20130274475A1 (en)	2013-10-17
FR20C1030I2 (fr)	2021-08-27
HUS000513I2 (hu)	2021-03-29
CN102827067A (zh)	2012-12-19
LTPA2020516I1 (lt)	2020-07-27
NO2020023I1 (no)	2020-08-10
PT2231667E (pt)	2013-12-13
KR20100130176A (ko)	2010-12-10
CN101918407A (zh)	2010-12-15
ME02089B (me)	2014-04-30
LTC2666774I2 (lt)	2022-01-25
ZA201005333B (en)	2011-04-28
HN2010001395A (es)	2012-11-12
NI201000115A (es)	2011-07-08
CY2020025I1 (el)	2020-11-25
AU2009206119A1 (en)	2009-07-23
JP5038509B2 (ja)	2012-10-03
JP5597164B2 (ja)	2014-10-01
CY1116243T1 (el)	2017-03-15
DOP2010000218A (es)	2010-08-31
HRP20131123T1 (hr)	2013-12-20
CY2020025I2 (el)	2020-11-25
FR20C1031I1 (da)	2020-02-10
HRP20150269T1 (hr)	2015-04-24
FR20C1032I1 (da)	2020-02-10
JP2011207900A (ja)	2011-10-20
MA32025B1 (fr)	2011-01-03
US8487093B2 (en)	2013-07-16
PT2666774E (pt)	2015-04-13
RS53052B (sr)	2014-04-30
EP2231667B1 (en)	2013-09-04
IL206395A (en)	2015-04-30
FR20C1030I1 (fr)	2020-02-10
NO2020024I1 (no)	2020-08-10
CN102827067B (zh)	2015-09-23
AU2009206119C1 (en)	2016-05-26
HUS000504I2 (hu)	2021-03-29
RU2445314C9 (ru)	2013-04-10
HK1186180A1 (en)	2014-03-07
ES2533826T3 (es)	2015-04-15
ECSP10010345A (es)	2010-08-31
WO2009091856A3 (en)	2009-12-03
IL206395A0 (en)	2010-12-30
BRPI0906871A2 (pt)	2020-07-28
CY2020023I2 (el)	2020-11-25
MX2010007823A (es)	2010-08-10
CO6331438A2 (es)	2011-10-20
CY2020024I1 (el)	2020-11-25
CN101918407B (zh)	2014-02-26
NL301050I2 (nl)	2020-09-03
LTPA2020518I1 (lt)	2020-07-27
PL2666774T3 (pl)	2015-06-30
NZ586861A (en)	2011-12-22
PL2231667T3 (pl)	2014-01-31
DK2666774T3 (da)	2015-03-23
JP2011510012A (ja)	2011-03-31
KR20160099117A (ko)	2016-08-19
WO2009091856A2 (en)	2009-07-23
US20110294777A1 (en)	2011-12-01
RU2445314C1 (ru)	2012-03-20
SI2231667T1 (sl)	2013-12-31
ES2433744T3 (es)	2013-12-12
ECSP10010568A (es)	2010-11-30
LTPA2020517I1 (lt)	2020-07-27
JP2012214475A (ja)	2012-11-08
EP2231667A2 (en)	2010-09-29
FR20C1031I2 (fr)	2022-07-29
HUS2000023I1 (hu)	2021-03-29
CR11626A (es)	2010-09-13
MY162532A (en)	2017-06-15
JP5422020B2 (ja)	2014-02-19
LUC00165I2 (da)	2021-08-16
CY2020024I2 (el)	2020-11-25

Publication	Publication Date	Title
CY2020025I2 (el)	2020-11-25	Αναστολεις βητα-λακταμασων
CY2017016I1 (el)	2017-07-12	Αναστολεις πρωτεασωματος
BRPI0917808A2 (pt)	2019-09-24	inibidores de cmet
BRPI0918564A2 (pt)	2015-12-01	inibidores
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0807547A2 (pt)	2014-06-17	Inibidores de aspartil protease hetercíclicos
ATE522535T1 (de)	2011-09-15	Pyrrolotriazin-kinasehemmer
BRPI0810374A2 (pt)	2014-10-29	Inibidores específicos do pdgfrbeta
BRPI0810365A2 (pt)	2014-10-29	Inibidores de mlc-1 de indol 7-substituído
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
EP2393898A4 (en)	2012-08-29	DUST SUPPRESSORS
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
DK2240506T3 (da)	2013-04-08	IAP inhibitorer
EP2177529A4 (en)	2011-04-20	NEW SECRETASE HEMMER
DK2331548T3 (da)	2013-12-16	Proteasehæmmere
BRPI0912564A2 (pt)	2019-09-24	inibidores de jnk
ATE522533T1 (de)	2011-09-15	Pyrazolopyrimidinonkinaseinhibitor
BRPI0919073A2 (pt)	2016-03-15	inibidores de protease
FI20075320A0 (fi)	2007-05-07	Uusia käyttökelpoisia inhibiittoreita
TH0801005303A (th)	2016-05-10	สารยับยั้ง c-fms ไคเนส